Rather under whelming response from BTA Managemant on the maiden sales and royaly from Inavir.
Following on from the GSK royalty disclosure tomorrow night it would be honest for BTA management to come out and fess up to their absolute lack of encouragement for the anti viral medicines they control.
Marketing 101 is not in their vocabulary.
How could they publish the latest anaylst report when it is deficient in detail and most probably contains errors as to the royalty rate for inavir.
BTA Price at posting:
$1.28 Sentiment: Buy Disclosure: Held
